Project Number SPB N°26
Chairs
Professor Maxime Dougados, Groupe Hospitalier Cochin, Paris, France.
Professor Andreas Radbruch, DRFZ, Berlin, Germany.
Abstract
The task force, comprising Europe’s leading researchers and clinicians, along with observers from a patients’ representative group and the European Medicines Agency, EMEA, has looked across the field of research and health care in rheumatic diseases, considering all aspects of basic research and clinical practice, and distilled its findings into five key recommendations:
1. To promote a pan-European research effort for a better understanding of the molecular and cellular basis of chronicity in rheumatic diseases for the development of curative and preventative strategies.
2. To promote coordinated European studies and trials in order to evaluate the incidence and outcome of rheumatic diseases and the development of prevention strategies.
3. To establish a pan-European network developing basic strategies for cell therapies of rheumatic diseases.
4. To promote a pan-European research effort towards a better understanding of the molecular and cellular pathology of osteoarthritis and osteoporosis.
5. To set up a Scientific Advisory Group (SAG) for rheumatic diseases at the European Medicines Agency (EMEA) with members from academia (i.e. basic, translational, clinical and epidemiological research) and patient organisations.
The aim is to provide coherent objectives for national and European funding bodies, healthcare providers, and ensure that rheumatic diseases are acknowledged as a major group of diseases within the European Commission Framework FP7.
Status
The Science Policy Briefing was published in June 2006 PDF253KB.
